The shelf registration signals a high likelihood of near-term equity issuance to fund ongoing clinical trials. With only ~2.6 quarters of cash at current burn, a follow-on offering is probable within months. Traders should watch for a prospectus supplement detailing actual terms and size of any takedown.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 8 $15.67entry
- T+1 · 5mo ago +8.49%α +8.78% · $17.00
- T+5 · 5mo ago +15.19%α +13.08% · $18.05
- T+20 · 4mo ago +30.25%α +28.62% · $20.41
- T+60 · due 3mo ago Pending
Price Chart
How similar events traded
Executive Summary
Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities (common, preferred, debt, warrants, etc.). The company is a clinical-stage biopharma with no revenue, burning ~$22M/quarter, and had $58.2M cash as of March 31, 2026. The shelf enables future capital raises, likely to fund Phase 2 celiac and other trials.
Key Financial Metrics
Key Facts
- Shelf registration of up to $500,000,000 in securities (common, preferred, debt, warrants, units)
- Pre-revenue clinical-stage biopharma with net loss of $22.1M in Q1 2026 vs $15.7M in Q1 2025
- Cash and cash equivalents of $58.2M as of March 31, 2026, down from $77.0M at Dec 31, 2025
- Operating cash burn of ~$22.4M/quarter; at current burn rate, cash runway extends ~2.6 quarters
- Lead candidate FB102 in Phase 2 celiac study (topline expected 2026), Phase 1b vitiligo and alopecia areata
- Market cap of $338M; shelf size of $500M is ~148% of current market cap, representing massive potential dilution
Financial Impact
Shelf registration of up to $500M, representing ~148% of current $338M market cap. Q1 2026 net loss of $22.1M, cash burn of ~$22.4M/quarter.
Risk Factors
- Massive potential dilution: shelf size ($500M) is 148% of current market cap ($338M)
- Cash runway of only ~2.6 quarters at current burn rate ($22.4M/quarter)
- Pre-revenue clinical-stage company with no approved products and uncertain pipeline timelines
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-260329 |
| Document: d117004dex231.htm | 0001193125-26-260329 |
| Document: 0001193125-26-260329-index-headers.html | 0001193125-26-260329 |
| Document: 0001193125-26-260329-index.html | 0001193125-26-260329 |
| Document: 0001193125-26-260329.txt | 0001193125-26-260329 |
Track record
15 reports on FBRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
- Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
- Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
- Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
- Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
- Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
- Jun 5, 202623w ago S-3/A Bearish 6/10 Viewing Entry $15.67 No price data
- Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers